ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Public Forum On NRSA Tuition Policies

April 14, 1995

Second-Generation CML Drugs Show Promise For Frontline

December 26, 2008

Moddelmog Steps Down At Komen For the Cure

November 20, 2009

5-FU/Levamisole A community Success Story; Trials With Untreated Control Revised Or Dropped

October 13, 1989

ACS Clinical Awards Available For 1996

March 31, 1995

NCAB Rejects Automatic Loss Of Comprehensive Status For Center Without Core Grants

September 29, 1978